Thrombopoietin receptor agonists (TPO-RAs) are used to treat immune thrombocytopenia (ITP), but predicting clinical response to TPO-RAs before initiation is not possible. To determine whether endogenous TPO levels predict treatment response to TPO-RAs we performed a retrospective analysis of ITP patients with known baseline TPO levels who received TPO-RAs. Data was collected for ITP patients with a baseline TPO level treated with eltrombopag or romiplostim.
| INTRODUCTION
The thrombopoietin (TPO) receptor agonists (RA) are a group of platelet growth factors that are now established as a mainstay of treatment for immune thrombocytopenia (ITP) 1,2 and have been approved or are under investigation for additional indications. [3] [4] [5] [6] The TPO-RAs currently approved for ITP treatment include the peptide agent romiplostim and the non-peptide agent eltrombopag. By way of their action at the TPO receptor c-Mpl, these agents increase megakaryocyte growth and differentiation and platelet production. Their efficacy in management of ITP is substantiated by the recognition that ITP is characterized not just by increased platelet destruction but also by inappropriately low platelet production. 7, 8 Patients with ITP display a wide range of clinical response to treatment with TPO-RAs, from a robust and durable therapeutic platelet count rise to no appreciable change in platelet count despite extended durations of ongoing therapy at maximal doses. Attaining a response may require weeks or months of gradual dose titration with interval platelet count assessment, as the dosing instructions in the prescribing information direct initiation at low doses to avoid thrombocytosis and consequent thrombotic risk. 9, 10 For those not achieving a response, this means a significant duration of severe or profound thrombocytopenia with all the attendant bleeding risk as well as a considerable financial investment, all without clinical benefit. Therefore, a reliable means to predict clinical response prior to initiation of TPO-RAs in the ITP population is a clear need.
TPO, the principle regulator of thrombopoiesis, is a peptide hormone produced constitutively by the liver and secreted into the circulation. Physiologic control of thrombopoiesis results from clearance of circulating TPO by platelets and megakaryocytes 11 and has been shown in multiple studies to be within the normal range or slightly elevated in the majority of ITP patients. [12] [13] [14] In consideration of the highly variable clinical response to TPO-RAs, it is possible that significant elevations of baseline endogenous TPO in some ITP patients may be one factor resulting in reduced clinical response. The analogous situation in erythropoiesis is well-established, as significantly elevated baseline levels of serum erythropoietin predict a poor response to erythropoiesis stimulating agents in many clinical circumstances. 15, 16 Furthermore, an inverse relation has been demonstrated between baseline endogenous TPO level and likelihood of response to treatment with romiplostim in patients with low-risk myelodysplastic syndromes and a model for predicting response in these patients integrating baseline TPO level has been developed and validated. 17 Although the predictive value of baseline endogenous TPO level for response to TPO-RA therapy in ITP has never been comprehensively examined, one prior study analyzing a small cohort of patients suggested the potential utility of this approach. Therefore, we sought to perform a critical examination of the relation between baseline endogenous TPO level and response to the TPO-RAs eltrombopag and romiplostim in a large cohort of ITP patients. As we routinely obtain TPO levels in patients with ITP at initial evaluation given its diagnostic utility in differentiating hypoproliferative thrombocytopenia from consumptive thrombocytopenia, 12, 14 we carried out a retrospective analysis of all ITP patients with baseline TPO level measurements who were treated with the TPO-RAs eltrombopag or romiplostim at our institution. 
| METHODS

| Patients and data collection
| Statistical analysis
Multiple logistic regression was used to model the probability of overall response, moderate response, and superior response to eltrombopag or romiplostim based on TPO level, number of previous therapies, splenectomy status, and duration of disease. As the classes of response were not ordinal (by definition each lower class included all patients in the classes above it), separate models were created for each. As response fraction is a proportion, a generalized linear model was used to model the logit transformation of the response fraction to allow for prediction of response fraction based on TPO level.
Receiver operating characteristic (ROC) analysis was performed and TPO level thresholds for optimal discrimination between responders and non-responders to romiplostim and eltrombopag treatment were Table 1 .
In the majority of cases, doses of romiplostim or eltrombopag were titrated in accordance with the prescribing information for each agent, although a strict dosing protocol was not in place. In all cases deemed to be non-responders to therapy, the maximal dose of a given agent according to the prescribing information (10 μg/kg/wk of romiplostim or 75 mg/d of eltrombopag) was attempted before the therapy was discontinued due to lack of response. 
| Logistic regression and generalized linear models of treatment response
Each multiple logistic regression model (all included TPO level, number of prior therapies, splenectomy status, and duration since ITP diagnosis as the independent variables) demonstrated a statistically significant relation between TPO level and probability of overall response, moderate response, or superior response for patients treated with either eltrombopag or romiplostim ( Table 2) . The generalized linear model used to model the response fraction included the same independent variables and showed a statistically significant relation between TPO level and response fraction for patients treated with either eltrombopag (P < .001) or romiplostim (P < .001). Illustrative predicted response fractions for several TPO levels based on the findings from this model are listed in Supporting Information Table S1 .
There was no statistically significant relation between any class of response or response fraction and any of the other independent variables in any model. For all classes of response, odds ratios (ORs) for probability of response based on TPO level were similar between the multiple logistic regression model (adjusted OR) and a single logistic regression model performed with TPO level alone as the sole independent variable (unadjusted OR) ( Table 2 ). Additionally, there was a statistically significant inverse correlation between TPO level and each class of response (Table 2 ). Probability models of overall response, moderate response, and superior response based on TPO level to eltrombopag and romiplostim are illustrated in Figure 1 . Model of predicted response fraction based on TPO level is illustrated in Figure 2 .
| ROC analysis for optimally discriminant TPO level thresholds
Utilizing Youden's index, the optimally discriminant TPO level threshold for overall response to eltrombopag was ≤136 pg/mL, which predicted a 96% (95% CI, 80%-100%) probability of response in those with a TPO level ≤136 pg/mL and an 82% (95% CI, 48%-98%) probability of non-response in those with a TPO level > 136 pg/mL. The optimally discriminant TPO level threshold for overall response to romiplostim was ≤209 pg/mL, which predicted an 89%
(95% CI, 73%-97%) probability of response in those with a TPO level ≤209 pg/mL and an 82% (95% CI, 48%-98%) probability of nonresponse in those with a TPO level > 209 pg/mL.
| Nonresponders treated with TPO-RA plus concurrent corticosteroids
In total 11 patients who did not achieve an overall response when 
| DISCUSSION
Although early studies of the pathophysiology of ITP suggested the major pathophysiologic mechanism was immune-mediated platelet destruction 20 with a compensatory 6-fold augmentation of platelet production by the bone marrow, 21 more recent investigations have determined that platelet production in ITP patients actually occurs at a nearly normal rate. This is due to the dual action of pathologic antiplatelet antibodies, which simultaneously opsonize platelets resulting in their clearance and bind to megakaryocytes and megakaryocyte progenitors, resulting in accelerated megakaryocyte apoptosis and an inadequate, near-normal rate of platelet production. 22 Unlike in the aplastic anemia patient, in which TPO levels are typically 10-fold higher than normal due to a lack of megakaryocytes and platelets to clear it, 13 platelets are being produced at a normal rate and megakaryocyte mass is intact in ITP patients. These platelets and megakaryocytes clear TPO at a normal rate despite their shortened survival, resulting in normal or modest elevations of TPO levels in most ITP patients. 11 Administration of TPO or TPO-RAs simultaneously increases the number of megakaryocyte precursors and reverses the apoptotic effect of antiplatelet antibodies on these cells, allowing for significantly increased platelet production.
11,23
In the context of this pathophysiology, an inverse relation between baseline TPO level and response to TPO-RA therapy is rational: those with substantial elevations of endogenous TPO at baseline stand to benefit less from the addition of an exogenous TPO-RA. Our study confirms this relation in a relatively large cohort of ITP patients receiving either eltrombopag or romiplostim, utilizing several multiple logistic regression models to demonstrate the impact of TPO level on the probability of response to therapy while controlling for the major potential confounders (number of prior lines of therapy, splenectomy status, and duration of disease) considered to be surrogates for severity of disease and responsiveness to treatment. Response fraction and 3 different classes of response were evaluated, and the inverse relation between TPO level and probability of response remained clearly evident and statistically significant regardless of how response was defined (Table 2 and Supporting Information Table S1 ). Overall response (response fraction >0.0) was analyzed as a low threshold to distinguish between patients with and without any meaningful response to TPO agonists; moderate response (response fraction ≥0.5) we think is representative of the minimum acceptable level of disease control for most ITP patients; and superior response (response fraction ≥0.8) is representative of optimal disease control. There was a moderately strong, statistically significant correlation between response fraction and TPO level for both agents, and a moderate correlation between median platelet count and TPO level, though this was only statistically significant for eltrombopag-treated patients.
ROC analysis established an optimal threshold TPO level for an overall response of ≤136 pg/mL for eltrombopag and ≤209 pg/mL for romiplostim. The finding that romiplostim was able to produce all 3 classes of clinical response at a higher baseline TPO level than eltrombopag is consistent with the established higher potency of romiplostim in healthy subjects as compared with eltrombopag. [24] [25] [26] The reduced effectiveness of eltrombopag as compared with romiplostim in patients with higher TPO levels was also demonstrated in the multiple logistic regression modeling (Table 2) , with an OR (per 10 pg/mL increase in baseline TPO level) of an overall response to eltrombopag of 0.524 vs 0.905 for romiplostim. Although an overall response as we define it is a relatively modest benchmark to achieve, the thresholds obtained by ROC analysis are intended to be most useful in predicting for whom TPO-RA therapy is unlikely to be of any significant benefit (ie, to avoid a treatment likely to be futile). Given the probability modeling demonstrated in Figure 1 and Figure 2 , the clinician can expect a higher likelihood of a meaningful clinical response with baseline TPO level significantly lower than these thresholds. occurring. It is also worth noting that the necessity of defining a numerical threshold for a clinical response (which in our study was ≥50 × 10 9 /L) is also a limitation of our study as some ITP patients achieve good long-term disease control below this threshold. We chose this threshold because it is adequate for the majority of ITP patients and considered sufficiently rigorous by most providers.
In conclusion, the results of our study suggest that obtaining a baseline serum TPO level in any ITP patient in whom TPO-RA agonist therapy is anticipated may be clinically useful. This TPO level may be obtained regardless of platelet count, as the baseline platelet count does not significantly affect TPO level in ITP patients, 28 and may be obtained at any time during the patient's disease course, as baseline TPO levels in ITP patients do not appear to be significantly affected by disease duration or whether or not a patient is receiving treatment. 12 Using logistic regression modeling, we demonstrated that ITP patients with normal TPO levels are likely to clinically respond to either eltrombopag or romiplostim, those with modest elevations of TPO are more likely to respond to romiplostim than eltrombopag, and those with extreme elevations in TPO are unlikely to respond to either agent. For the latter group, addition of low-dose prednisone to maximal TPO-RA treatment may achieve a response. Using an ROC analysis, we found optimal TPO thresholds for discrimination of responders from non-responders of ≤136 pg/mL for eltrombopag treatment and ≤209 pg/mL for romiplostim treatment. While our study is the most detailed and comprehensive to date to examine this question, confirmation of our findings with a prospective study would be helpful.
